Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Clinical trial NCT04643795 · COMPLETED
Trial details
- NCT number
- NCT04643795
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-25
- Primary completion
- 2021-08-04
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.